Inovio Receives First FDA Approval for a DNA Medicine, Voceryq, for Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals has received accelerated FDA approval for Voceryq (formerly INO-3107), marking it as the first U.S. FDA-approved DNA medicine. The drug is designed to reduce the frequency of surgery for adults with recurrent respiratory papillomatosis, a rare HPV-driven disease causing wart-like growths in the throat and airways. The approval was granted on October 30, 2026.